Analyst firms · Morgan Stanley · ABT
Morgan Stanley ABT price target and rating history
Abbott Laboratories (ABT) · Health Care
Morgan Stanley rates Abbott Laboratories (ABT) Equal-Weight with a $112 price target, as of its latest action on May 30, 2023. It has published 5 rating actions on ABT since July 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a ABT price target in the last 12 months, the median target is $121.
- Current rating
- Equal-Weight
- Price target
- $112
- Median target, all firms
- $121
- Actions on ABT
- 5
Morgan Stanley price target on ABT
Every Morgan Stanley rating on ABT
- May 30, 2023
- Jan 27, 2022
- Jan 7, 2022
- Oct 21, 2021
- Jul 23, 2021
How other firms rate ABT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Hold | Oct 27, 2026 | |
| Barclays | Overweight | $120 | Oct 7, 2026 |
| Rothschild & Co Redburn | Buy | $127 | Oct 2, 2026 |
| Wolfe Research | Outperform | $130 | Aug 13, 2026 |
| Robert W. Baird | Outperform | $121 | Jul 1, 2026 |
| Daiwa | Neutral | $92 | Apr 22, 2026 |
Questions about Morgan Stanley and ABT
- What is Morgan Stanley's price target for ABT?
- Morgan Stanley's latest stated price target for Abbott Laboratories (ABT) is $112, from its action on May 30, 2023.
- What is Morgan Stanley's rating on ABT?
- Morgan Stanley rates ABT Equal-Weight, a neutral rating, as of May 30, 2023.
- When did Morgan Stanley last change its view on ABT?
- On May 30, 2023, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $112.
- How does Morgan Stanley's ABT target compare with other analysts?
- Across 5 firms with a ABT price target in the last 12 months, the median target is $121.
More ABT rating histories
All Morgan Stanley ratingsABT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.